In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Alnylam, Vir ally in deal worth potentially over $1bn

Executive Summary

In its second agreement announced on the same day Vir Biotechnology Inc. is partnering with Alnylam Pharmaceuticals Inc. in the development of up to five RNAi therapies for infectious diseases, including chronic hepatitis B virus.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information

Related Companies

UsernamePublicRestriction

Register